Tesamorelin
GHRH Analog (approved for HIV lipodystrophy)
Randomized trials support tesamorelin for visceral fat reduction in HIV-associated lipodystrophy, where it is approved; its use for general fat loss, muscle, or 'anti-aging' is unstudied and unproven.
How confident is BioSignal?
Our overall position, and how sure we are of it across each dimension — including where we are not sure at all.
Moderate confidence
Randomized trials support tesamorelin for visceral fat reduction in HIV-associated lipodystrophy, where it is approved; its use for general fat loss, muscle, or 'anti-aging' is unstudied and unproven.
Promising evidence that is still developing or context-dependent.
Human Evidence
Two RCTs + approval for HIV lipodystrophy; none for general/anti-aging use.
Mechanistic Plausibility
GHRH analog → GH/IGF-1 → visceral lipolysis.
Research Activity
Studied in HIV lipodystrophy and liver fat; limited beyond.
Safety Profile
Raises IGF-1 (glucose and theoretical neoplastic concerns); injection-site reactions; not for pregnancy.
Consensus
Approval/guideline support only for HIV-associated lipodystrophy.
Where the evidence stands today
How mature the science is, what kinds of evidence exist, and — the part nobody else prints — what is still missing.
9/9
steps proven in humans
Evidence-rich
Proven at every applicable step — rare, and worth noticing.
Guideline / regulatory support
ProvenApproved for HIV lipodystrophy; Absent for general use.
Clinical outcomes
ProvenVisceral/liver fat reduction (HIV indication).
Large human RCTs
ProvenFalutz 2007, Stanley 2014 (HIV).
Small human outcome trials
ProvenEarly-phase efficacy (HIV).
Human safety data
ProvenEstablished in the HIV population.
Human biomarker / pharmacology
ProvenIGF-1 and fat measures.
Animal
ProvenPreclinical.
Cell / in vitro
ProvenReceptor pharmacology.
Mechanistic plausibility
ProvenGHRH analog → GH/IGF-1 → visceral lipolysis.
The bottom line
What we know, what we think, what we don't know — and what would change our mind.
Works for HIV visceral fat
In RCTs, tesamorelin reduced visceral adipose tissue in HIV-associated lipodystrophy and reduced liver fat; it is FDA-approved for that indication.
A targeted therapy
It is a targeted therapy for a specific problem (HIV visceral fat), not a general fat-loss or anti-aging drug.
General-use and long-term questions
Efficacy and safety for the general population and long-term neoplastic risk from sustained IGF-1 elevation are unknown.
Liver-fat research
Liver-fat / MASH research in HIV populations continues.
What would change the picture
Randomized outcome data in non-HIV populations would be needed before any general-use claim.
The biggest myth
“The benefit lasts after you stop.”
Visceral fat tends to re-accumulate after discontinuation; it is a maintenance therapy.
Ask BioSignal
Still have a question about tesamorelin?
Answers are retrieved from this record and the rest of the knowledge graph — never generated.
Why people take tesamorelin
Popularity is not evidence — but it is not stupid either. This explains the interest on its own terms.
People search tesamorelin for belly-fat reduction and 'anti-aging' GH effects. Interest exceeds evidence outside its narrow approval: it works for HIV-associated visceral fat, but there is no evidence for general fat-loss, muscle, or anti-aging use, and it is prohibited in sport.
If you're here because…
Jump straight to the part of the evidence that answers your question.
Approval, safety and regulatory
What it is approved for, who should be careful, what remains unknown — and the limits of what this evidence can tell you.
Regulatory status
Approved (HIV-associated lipodystrophy)
Availability
Approved prescription (narrow indication)
Sport (WADA)
Prohibited (GHRH analog, S2.2) — confirm at publication
Known safety profile
Injection-site reactions; IGF-1 elevation; possible glucose intolerance; arthralgias, edema, flushing.
Common issues
- Injection-site reactions
- IGF-1 elevation
- Fluid retention / arthralgia
Use caution if
- Active malignancy (contraindicated)
- Pregnancy
- Diabetes/prediabetes (glucose monitoring)
- Anyone outside the studied HIV population (unstudied)
Long-term unknowns
Multi-year neoplastic and metabolic safety.
Limits of this evidence
Efficacy data are confined to HIV-associated lipodystrophy; industry-sponsored (disclosed).
Full regulatory and sport detail
- Regulatory approval
- Approved (EGRIFTA / EGRIFTA WR).
- Approved indication
- Reduction of excess abdominal fat in HIV-associated lipodystrophy.
- Investigational
- Liver-fat / MASH research in HIV populations.
- Research chemical
- N/A for the approved product (unregulated copies exist).
- Compounding
- Not applicable (approved drug).
- Sport (WADA)
- GHRH analogs are prohibited (S2.2) even though tesamorelin is approved — confirm at publication.
- Publication note
- Re-confirm regulatory and anti-doping status against primary sources at publication.
Demand, separated from evidence
Every claim people make about this, counted against what the evidence actually showed.
BioSignal evaluated 4 popular claims about tesamorelin.
Here is where each one landed — including the claims of harm, where “not established” is reassuring rather than damning.
- Supported by evidence
- 1
- Not established
- 3
Popularity is not evidence. This is simply a count of every claim BioSignal evaluated on this page, sorted by what the evidence actually showed — the full reasoning behind each verdict is in the Evidence Review below.
Supported by evidence
- Tesamorelin reduces visceral and liver fat in HIV-associated lipodystrophy.
Not established
- The benefit lasts after you stop.
- Tesamorelin is a general anti-aging / fat-loss / muscle drug.
- It's allowed for athletes.
The evidence review
Every claim with the reasoning behind its verdict, the doses actually studied, where scientists agree and disagree, and the questions still open.
What people claim
Every popular claim, with BioSignal’s verdict and how confident we are in it. The verdicts are always visible; open any claim to read the evidence behind it.
Tesamorelin reduces visceral and liver fat in HIV-associated lipodystrophy.SupportedModerate confidence
Randomized trials show reduced visceral and liver fat in this population; it is approved for it.
Tesamorelin is a general anti-aging / fat-loss / muscle drug.Not establishedModerate confidence
No trials outside HIV-associated lipodystrophy; raising GH/IGF-1 in healthy adults is unproven and carries risk.
It's allowed for athletes.Not establishedLimited evidence
GHRH analogs are prohibited in sport (WADA S2), even though tesamorelin is an approved drug.
Doses used in human studies
What was actually given to participants in the research. These are descriptions of studies, not recommendations.
HIV-associated lipodystrophy
- Intervention
- Tesamorelin SC daily
- Dose
- 2 mg/day
- Duration
- 26–52 weeks
- Outcome
- ↓ visceral adipose tissue (Falutz 2007)
- Notes
- Descriptive of the approved indication.
HIV + abdominal / liver fat
- Intervention
- Tesamorelin SC daily
- Dose
- 2 mg/day
- Duration
- 6 months
- Outcome
- ↓ liver fat (Stanley 2014)
- Notes
- Prescribing is a clinician's decision.
Where scientists agree — and don’t
Agreed
- Effective for visceral/liver fat in HIV-associated lipodystrophy
- Approved for that use
Debated
- Durability
- Long-term IGF-1-related risk
- Any role beyond HIV populations
Unknown
- General-population efficacy/safety
- Long-term neoplastic and metabolic risk
What remains unknown
- Does it help outside HIV-associated lipodystrophy?
- What are the long-term consequences of sustained IGF-1 elevation?
- How durable is the benefit, and what is the optimal duration?
Questions people actually ask
Is tesamorelin an anti-aging drug?
No. It is approved only to reduce excess abdominal fat in HIV-associated lipodystrophy. There is no evidence for general anti-aging, fat-loss, or muscle use, and it raises IGF-1, which carries its own risks.
Do the effects last after stopping?
Generally no — visceral fat tends to re-accumulate after discontinuation, so it functions as a maintenance therapy.
Practical takeaways
- Tesamorelin is a real, approved therapy — but only for HIV-associated lipodystrophy.
- Its benefits reverse on stopping; it is maintenance therapy, not a cure.
- It raises IGF-1, with glucose and theoretical cancer-risk considerations.
- There is no evidence for general anti-aging, fat-loss, or muscle use.
- It is a prescription drug and is prohibited in sport — not a casual peptide.
How it works
The mechanism comes last on purpose. A compelling explanation of how something might work is the easiest part of the story to tell, and the part most likely to outlive the evidence for it.
How we found out
2007 — Falutz (NEJM)
Reduced visceral fat in HIV-associated lipodystrophy.
2010 — FDA approval (EGRIFTA)
For HIV-associated lipodystrophy.
2014 — Stanley (JAMA)
Reduced liver fat in HIV patients with abdominal fat.
References
Verified sources. BioSignal does not print a citation it has not checked.
- 01
Metabolic effects of a growth hormone-releasing factor in patients with HIV
N Engl J Med 357(23):2359-2370 · 2007
- 02
Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial
JAMA 312(4):380-389 · 2014
Version history
1.0
Initial review-hardened record (Established for approved indication; not-established for general use). Review cadence: Annual.
Continue exploring
Three places this record leads next.